Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates Roivant Sciences is in discussion with the US, Europe and Asian regulators to develop gimsilumab for treating acute respiratory distress syndrome (ARDS) caused by Covid-19.
Gimsilumab is a fully human monoclonal antibody, which targets granulocyte-macrophage colony-stimulating factor (GM-CSF), found to be up-regulated in the serum of Covid-19 patients.
UCLA Connective Tissue Disease-Related Interstitial Lung Disease Program founder and co-director Dr Elizabeth Volkmann said: “Up-regulation of GM-CSF appears to characterise progression to ARDS and death in Covid-19.